Recent consumer study challenges the conventional wisdom that a .com domain is essential for brand credibility SAUSALITO, Calif., April 9, 2026 /PRNewswire-PRWeb/ -- New consumer research from Lexicon ...
THE WOODLANDS, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it entered into a loan facility with Oxford Finance LLC that provides up to $150 ...
The fair value estimate for Lexicon Pharmaceuticals sits at US$3.36, with recent price target moves on the Street leaning on how analysts now frame pilavapadin and the broader risk profile of the ...
Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...
Sanofi has terminated a nearly four-year-old, potentially $1.7 billion-plus collaboration with Lexicon Pharmaceuticals to develop ZynquistaTM (sotagliflozin) for type 1 and type 2 diabetes after the ...
Lexicon Pharmaceuticals spent years jumping and often falling over regulatory hurdles for its new heart drug Inpefa, but, after finally getting an FDA approval this year, it’s now turning to Tom ...
An explosion in data volumes, proliferation of platforms, and evolving regulatory requirements has made effective monitoring of employee communications much more difficult. The remote and hybrid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results